Shares of Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) traded up 5.7% during mid-day trading on Tuesday . The stock traded as high as $45.72 and last traded at $45.58, with a volume of 398,130 shares changing hands. The stock had previously closed at $43.11.

Several analysts have issued reports on the stock. Wedbush reaffirmed an “outperform” rating and issued a $113.00 price objective on shares of Pacira Pharmaceuticals in a research report on Wednesday, April 20th. Mizuho began coverage on shares of Pacira Pharmaceuticals in a research report on Tuesday, April 19th. They set a “buy” rating and a $79.00 price target for the company. Canaccord Genuity reissued a “buy” rating on shares of Pacira Pharmaceuticals in a research report on Wednesday, April 20th. Zacks Investment Research raised shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, April 26th. Finally, TheStreet downgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 2nd. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $72.73.

The stock’s 50 day moving average price is $37.51 and its 200-day moving average price is $49.29. The company’s market cap is $1.69 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Thursday, August 4th. The company reported $0.19 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.16. The company earned $69.60 million during the quarter, compared to analyst estimates of $67.80 million. The firm’s revenue for the quarter was up 17.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.20 earnings per share. On average, equities analysts anticipate that Pacira Pharmaceuticals Inc. will post $0.30 EPS for the current fiscal year.

In other Pacira Pharmaceuticals news, CAO Kristen Marie Williams sold 600 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $47.20, for a total value of $28,320.00. Following the transaction, the chief accounting officer now directly owns 6,900 shares of the company’s stock, valued at approximately $325,680. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Mark A. Kronenfeld sold 900 shares of Pacira Pharmaceuticals stock in a transaction that occurred on Monday, June 6th. The stock was sold at an average price of $46.95, for a total value of $42,255.00. Following the completion of the transaction, the director now directly owns 2,950 shares in the company, valued at $138,502.50. The disclosure for this sale can be found here.

A number of hedge funds and institutional investors have modified their holdings of the company. Mutual of America Capital Management LLC increased its position in shares of Pacira Pharmaceuticals by 0.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 24,198 shares of the company’s stock valued at $1,858,000 after buying an additional 142 shares in the last quarter. Stephens Inc. AR boosted its stake in Pacira Pharmaceuticals by 3.9% in the fourth quarter. Stephens Inc. AR now owns 21,557 shares of the company’s stock worth $1,655,000 after buying an additional 806 shares in the last quarter. Rhumbline Advisers boosted its stake in Pacira Pharmaceuticals by 8.0% in the fourth quarter. Rhumbline Advisers now owns 42,471 shares of the company’s stock worth $3,261,000 after buying an additional 3,160 shares in the last quarter. New York State Common Retirement Fund boosted its stake in Pacira Pharmaceuticals by 38.1% in the fourth quarter. New York State Common Retirement Fund now owns 57,483 shares of the company’s stock worth $4,414,000 after buying an additional 15,867 shares in the last quarter. Finally, Morgan Stanley boosted its stake in Pacira Pharmaceuticals by 28.7% in the fourth quarter. Morgan Stanley now owns 120,614 shares of the company’s stock worth $9,261,000 after buying an additional 26,865 shares in the last quarter.

Pacira Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.